The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions
Authors:
- 1 December 2006
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 15 (3) , 251-257
Abstract
Adverse drug interactions are major causes of morbidity, hospitalizations, and mortality. The greatest risk of drug interactions occurs through in the cytochrome system. CYP3A4, the most prevalent cytochrome, accounts for 30–50% of drugs metabolized through type I enzymes. Palliative patients received medications for symptoms and co-morbidities, many of which are substrate, inhibitors, or promoters of CYP3A4 activity and expression. A literature review on CYP3A4 was performed pertinent to palliative medicine. In this state of the art review, we discuss the CYP3A4 genetics, and kinetics and common medications, which are substrates or inhibitor/promoters of CYP3A4. We made some recommendations for drug choices to avoid clinically important drug interaction.Keywords
This publication has 45 references indexed in Scilit:
- Buprenorphine: Considerations for Pain ManagementJournal of Pain and Symptom Management, 2005
- Pharmacokinetics and Pharmacodynamics of Systemically Administered GlucocorticoidsClinical Pharmacokinetics, 2005
- Newer Systemic Antifungal AgentsDrugs, 2004
- Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone AntibacterialsClinical Pharmacokinetics, 2001
- Pharmacokinetics of HaloperidolClinical Pharmacokinetics, 1999
- CiprofloxacinDrugs, 1996
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Macrolide AntibacterialsDrug Safety, 1995
- Metabolism of Drugs by Cytochrome P450 3A IsoformsClinical Pharmacokinetics, 1995
- Prescribing practices of a palliative care serviceJournal of Pain and Symptom Management, 1993